#USA #Lund #Hansa Biopharma #imlifidase #kidney transplantation

Hansa Biopharma Submits BLA for Imlifidase

Hansa Biopharma AB recently announced a significant step in the world of transplantation—it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its innovative treatment, Imlifidase. This application comes with the request for priority review, indicating the urgency and potential impact of this therapy in desensitizing highly sensitized adult patients who are eligible for deceased donor kidney transplants.

The submission is rooted in findings from the pivotal Phase 3 ConfIdeS trial, which has shown impressive results in evaluating kidney function among highly sensitized patients. Specifically, these patients exhibited a calculated panel reactive antibody (cPRA) level of 99.9% or greater, marking them as particularly challenging candidates for kidney transplants due to their heightened immune responses against potential donors.

Significant Trial Results
The ConfIdeS trial involved 64 highly sensitized patients who underwent kidney transplantation after being treated with Imlifidase. The primary endpoint of the trial measured kidney function over a 12-month period, showing that patients who received Imlifidase exhibited statistically significant improvements in their estimated glomerular filtration rate (eGFR) compared to those who did not receive the treatment. This improvement suggests that the enzyme is highly effective at mitigating the immune responses that have previously obstructed transplant success in sensitized individuals.

Renée Aguiar-Lucander, the CEO of Hansa Biopharma, stated, "The submission of the BLA to the FDA marks a pivotal milestone for Hansa Biopharma and for highly sensitized patients living with end-stage renal disease in the U.S." This statement underscores the transformative potential of Imlifidase, signaling hope for many patients facing life-threatening conditions compounded by the complexities of organ transplantation.

The Mechanism of Action
Imlifidase, an enzyme derived from Streptococcus pyogenes, is designed to cleave immunoglobulin G (IgG) antibodies in a rapid and efficient manner. This mechanism works both within and outside blood vessels to inhibit IgG-mediated immune responses, which are critical in organ rejection scenarios. By lowering the levels of these antibodies that contribute to hyper-sensitization, Imlifidase not only opens the door for formerly ineligible patients but also addresses a major barrier to kidney transplantation.

The FDA's recognition of Imlifidase’s importance is apparent through its designation of Fast Track and Orphan Drug status for this drug, reflecting the unmet medical needs of this patient population. If prioritized, the FDA could deliver a decision on the application as early as the third quarter of 2026, highlighting the anticipation surrounding this potential approval.

Looking Ahead
With over 170,000 patients in the U.S. and Europe on waiting lists for kidney transplants, the urgency for solutions like Imlifidase cannot be overstated. Imlifidase is already conditionally approved in Europe and other countries under the brand name IDEFIRIX. If granted FDA approval, Hansa Biopharma aims to improve access and outcomes for a demographic that has long faced significant challenges in organ transplantation.

The ongoing research into Imlifidase represents a promising venture in the biopharmaceutical field, particularly for patients grappling with rare immunological conditions. Hansa Biopharma's commitment to addressing these unmet needs is evident, as the company expands its portfolio of life-altering treatments aimed at improving lives and health outcomes.

Hansa Biopharma's work exemplifies how innovation, driven by rigorous clinical trials and patient-centered approaches, can reshape healthcare landscapes. The company's progress with Imlifidase sets a new precedent in the field of transplantation, advocating for better treatment access for a vulnerable population. While the coming months are critical, the submission of the BLA represents a beacon of hope for many in need.